# ArtiQ NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/artiq

- Industry: Healthcare IT
- Headquarters: Leuven, Belgium
- Website: www.artiq.eu
- Total disclosed funding: $1.1M
- Latest round: Seed (Jun 9, 2019)
- Investors on record: 3

## About

Founded in 2019 and based in Leuven, Belgium, ArtiQ NV operates as a health-tech company that provides an automated interpretation platform for pulmonary function tests to evaluate the patient's lung function and diagnose pulmonary diseases. Some of the firm's partners are EIT Health, NHS, Clario, Vyaire Medical, AstraZeneca, etc. In April 2024, Clario, a portfolio company of Nordic Capital, Novo Holdings, Cinven, and Astorg, acquired ArtiQ NV from UZ LEUVEN, KBC Group, and K.U. The firm as of July 2024, is led by its co-founders, Marko Topalovic (CEO), Marko Topalovic (Board Member), Bart Swaelens (Strategic Development), and Wim (Board Member, Medical & Scientific Advisor).

The company offers a range of AI-driven products tailored to respiratory care and clinical research, to enhance diagnostic accuracy and streamline clinical trials. These include ArtiQ.PFT, ArtiQ.QC, and ArtiQ.PFT. ArtiQ.RBM provides automated support for interpreting pulmonary function tests, ensuring consistency and adherence to the latest guidelines. ArtiQ.QC delivers real-time AI-based over-reading for spirometry, enhancing data quality and reducing variability. ArtiQ.RBM focuses on risk-based monitoring, aiming to safeguard data integrity in clinical trials.

## Funding rounds

- Seed, Jun 9, 2019, $1.1M — K.U. Leuven Research & Development, KBC Group, UZ LEUVEN

## Investors

- K.U. Leuven Research & Development (https://capitalatlas.ai/funds/k-u-leuven-research-development) — Seed
- KBC Group — Seed
- UZ LEUVEN — Seed